HOTH News and Press, Hoth Therapeutics Inc. From 02/08/21

Hoth Therapeutics ([[HOTH]] +9.6%) has signed an agreement with Camargo Pharmaceutical Services to facilitate the writing and submission of the Investigational New Drug application for its HT-001 topical product to the U.S. FDA for initiating the first clinical trial.The company will write, p...

Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients The IND submission will facilitate initiation of clinical trials for HT-001 in early 2022 PR Newswire NEW YORK , Feb. 8, 2021 /PRNewswire/ -- H...

Hoth Therapeutics (HOTH) provides pipeline updates and highlights that it has scheduled to start an early-stage clinical trial for its BioLexa Platform, designed for the treatment of atopic dermatitis, in the first quarter of 2021.The company has been granted a Pre-IND meeting ...

Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline PR Newswire NEW YORK , Feb. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipe...

Hoth Therapeutics (HOTH) announces extension of its research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent, for the treatment of acne.The 1-year agree...

Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research The extended research agreement builds on the positive results generated for HT-003 as an acne therapeutic PR Newswire ...

Hoth Therapeutics Announces the Appointment of Mario E. Lacouture, M.D. to Oversee Dermatology Therapeutic Program for Cancer Patients as Part of Hoth Scientific Advisory Board Dr. Lacouture will oversee the development of Hoth's Proprietary HT-001 for patients receiving EGFR in...

Hoth Therapeutics (HOTH) gains 8% in premarket in reaction to new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.Data fr...

Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication Initial data reports one of the most critical signaling pathways for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003 ...

Acorda Therapeutics (ACOR) +54% after announcing agreement for sale of manufacturing operations and long-term global supply agreement.Summit Midstream Partners (SMLP) +45% after winning FERC construction OK.WiMi Hologram Cloud (WIMI) +38% on obtaining a patent for a 3D holograp...